Alzheimer's polypill shows promise in early trial
NCT ID NCT06597058
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This Phase 2 study tested a once-daily combination pill (polypill) in 121 adults aged 50–85 with very mild to severe Alzheimer's disease. Over 180 days, researchers measured changes in thinking, memory, and daily function using standard dementia scales. The goal was to estimate whether the polypill could slow decline compared to a placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Accel Research Sites (Noah Clinical Site 019)
DeLand, Florida, 32720, United States
-
Best Choice Medical and Research Service (Noah Clinical Site 025)
Pembroke Pines, Florida, 33024, United States
-
Boston Clinical Trials (Noah Clinical Site 006)
Boston, Massachusetts, 02131, United States
-
Carolina Research Center, Inc. (Noah Clinical Site 009)
Shelby, North Carolina, 28150, United States
-
Denali Health Plant City, LLC (Noah Clinical Site 024)
Plant City, Florida, 33563, United States
-
Health Awareness (Noah Clinical Site 020)
Jupiter, Florida, 33458, United States
-
IMA Clinical Research (Noah Clinical Site 004)
Albuquerque, New Mexico, 87109, United States
-
International Medical Investigational Centers (Noah Clinical Site 001)
Palmetto Bay, Florida, 33176, United States
-
Life Well Research Center (Noah Clinical Site 008)
Miami, Florida, 33134, United States
-
Marvel Clinical Research (Noah Clinical Site 010)
Huntington Beach, California, 92647, United States
-
Miami Jewish Health (Noah Clinical Site 023)
Miami, Florida, 33137, United States
-
Neurology Associates of Ormond Beach (Noah Clinical Site 015)
Ormond Beach, Florida, 32174, United States
-
Olympus Clinical Research (Noah Clinical Site 014)
Katy, Texas, 77450, United States
-
Regenerate Primary Medical Research (Noah Clinical Site 003)
Miami, Florida, 33134, United States
-
Scottsdale Clinical Trials (Noah Clinical Site 017)
Scottsdale, Arizona, 85260, United States
-
Tekton Research (Noah Clinical Site 002)
Yukon, Oklahoma, 73099, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
a combination of multiple drugs in a single once-daily tablet (polypill)
What this could lead to
If this polypill shows benefit, it could point toward a new way to slow cognitive decline in Alzheimer's disease.
What could go wrong
This is an early Phase 2 study with only 121 participants, so results may not be conclusive. The polypill's effects are still uncertain, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.